Liquid biopsy – the future of early cancer detection
Cancer is the second most common cause of death worldwide. In addition to advanced therapeutic approaches, early detection is the key to improving quality of life and the chances of survival. The analysis of cancer-related signals using biological fluids – liquid biopsy – has made enormous progress in the last decade. Using the special Liquid Biopsy test that we offer at the Swiss Center for Health & Longevity, we can identify a wide range of biomolecular characteristics for early cancer detection. Long before the disease produces symptoms or even becomes palpable.
Why we use the liquid biopsy
Tissue biopsies are currently the gold standard in cancer diagnostics. However, they are not really practical either for early cancer detection or for the follow-up of cancer patients. With the help of a liquid biopsy, we can obtain valuable information and indications of cancer in a minimally invasive way using a simple blood sample. The test uses circulating tumor DNA (ctDNA), circulating tumor cells and many other substances to detect the presence of solid tumors in the blood.
Crucial test for longevity
The liquid biopsy test we use detects circulating tumor cells (CTCs) and CTC clusters that are released into the bloodstream by malignant tumors, but not by benign tumors or healthy tissue. CTCs are ubiquitous in the blood of cancer patients, whereas they are not present in the blood of healthy individuals. With this test we can detect about 70 solid tumors, which are responsible for about 81% of all cancer cases and about 84% of all cancer-related deaths in Europe. Clinical studies have shown a sensitivity of 88% in the detection of cancer at all stages.
Don’t give cancer a chance! Whether liquid biopsy or full-body MRI – state-of-the-art early detection can be the decisive factor for successful and, above all, timely treatment!
